Budesonide
FDA approves Airsupra, fixed-dose combination rescue asthma inhaler for adults
The FDA approved a pressurized metered-dose inhaler with a fixed-dose combination of albuterol and budesonide for use as rescue medication among patients with asthma aged 18 years and older, according to a manufacturer-issued press release.
AGA releases 10 best practice statements for management of refractory celiac disease
In an expert review published in Gastroenterology, AGA provided updated guidance for the diagnosis and management of refractory celiac disease, including supportive and therapeutic treatment options and recommendations for monitoring.
Albuterol-budesonide decreases asthma deteriorations, exacerbations
LOUISVILLE, Ky. — Patients treated with albuterol and budesonide experienced less asthma deteriorations and exacerbations over 12 weeks compared with patients who received the mono-components or placebo, according to DENALI study results.
FDA panel supports approval of two-drug asthma inhaler for adults, split on adolescents
The FDA’s Pulmonary-Allergy Drug Advisory Committee voted 16-1 in favor of approving the fixed-dose combination of budesonide and albuterol sulfate metered dose inhaler for patients with asthma aged 18 years and older.
Fixed-dose albuterol-budesonide rescue inhaler cuts severe asthma attack risk: MANDALA
SAN FRANCISCO — In patients with uncontrolled moderate to severe asthma, a fixed-dose combination of albuterol and budesonide used as an as-needed rescue medication lowered risk for severe asthma exacerbations compared with albuterol alone.
Top in GI: AI-assisted colonoscopy, FDA denial of budesonide for eosinophilic esophagitis
A new study showed that artificial intelligence-assisted colonoscopy increased the adenoma detection rate in patients at average risk for colorectal cancer. It was the top story in gastroenterology last week.
FDA approves first generic of Symbicort for asthma, COPD
The FDA announced approval of the first generic of Symbicort — budesonide and formoterol fumarate dihydrate — Inhalation Aerosol for the treatment of asthma and COPD, according to an agency press release.
FDA rejects new drug application from Takeda for budesonide for EoE
Takeda Pharmaceutical Company Limited announced it received an FDA complete response letter in response to its new drug application for TAK-721 for the treatment of eosinophilic esophagitis, according to a release.
Budesonide improves histologic, symptom response in pediatric EoE
Budesonide oral suspension improved histologic, endoscopic and symptom response compared with placebo among pediatric patients with eosinophilic esophagitis, according to a study.
Budesonide tablets effectively increase esophageal distensibility in EoE
During induction, budesonide tablets were effective in increasing esophageal distensibility in eosinophilic esophagitis and was further improved during maintenance therapy, according to a presenter at UEG Week.